Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab in Idiopathic Pulmonary Fibrosis
NCT05515627Phase 1Active, not recruiting
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Feb 2023
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of atezolizumab in idiopathic pulmonary fibrosis (IPF), sponsored by Cedars-Sinai Medical Center. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 24 weeks. Started Feb 2023; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05515627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05515627.